Abstract: A method for producing nanostructured coatings on a substrate, comprising: preparing a nanocrystalline powder of a powder size comprised between 1 and 60 ?m; and combining cleaning the surface of the substrate and cold spraying the nanocrystalline powder on the surface of the substrate, and a system for producing nanocrystalline coatings on a substrate, comprising a spray head, a cleaning head and a handling system monitoring the spray head and the cleaning head relative to the substrate to be coated, the spray head being a first cold spray head, the first cold spray head depositing on the substrate at least one nanocrystalline powder, the cleaning head optimizing the surface being coated with the at least one layer of nanocrystalline powder.

Abstract: The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

Abstract: A method for preparation of highly porous and preferentially-oriented {100} platinum on a substrate by electrodeposition in a deposition bath, comprising using a deposition potential Edep lower than ERHE+150 mV and an acidified platinum salt solution having a Pt salt concentration less than 5.0 mmole L?1 or, in presence of hydrogen, comprising limiting the concentration of Pt salts in the electrolyte to less than 5.0 mmole L?1 and controlling the temperature of the electrolyte. Preferentially-oriented {100} platinum nanowires and thin films, comprising Pt{100} in a range between about 20 and about 60% and having a roughness factor of at least 50 are produced.

Abstract: The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

Abstract: A method for producing nanostructured coatings on a substrate, comprising: preparing a nanocrystalline powder of a powder size comprised between 1 and 60 ?m; and combining cleaning the surface of the substrate and cold spraying the nanocrystalline powder on the surface of the substrate, and a system for producing nanocrystalline coatings on a substrate, comprising a spray head, a cleaning head and a handling system monitoring the spray head and the cleaning head relative to the substrate to be coated, the spray head being a first cold spray head, the first cold spray head depositing on the substrate at least one nanocrystalline powder, the cleaning head optimizing the surface being coated with the at least one layer of nanocrystalline powder.

Abstract: Fused pyrimidine compounds of structural formula (I) are effective as antagonists of the biological activity of the GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and Metabolic Syndrome.

Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases, Formula (I). The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula 1. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases. Formula (I). The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula 1. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

Abstract: The invention is directed to a method for treating a cyclooxygenase-2 mediated disease or condition in a mammalian patient at risk of a thrombotic cardiovascular event, wherein the patient is on aspirin therapy to reduce the risk of the thrombotic cardiovascular event, comprising orally concomitantly or sequentially administering to the patient a cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediate disease or condition, and a nitric oxide donating compound in accordance with Formula I or a pharmaceutically acceptable salt thereof, wherein the nitric oxide donating compound is administered in an amount effective to reduce the gastrointestinal toxicity caused by the combination of the cyclooxygenase-2 selective inhibitor and aspirin. Pharmaceutical compositions are also encompassed.

Abstract: Novel cycloalkanoindole derivatives of formula (I) are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.

Abstract: Dihydropyrroloindoles and tetrahydropyridoindoles are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.

Abstract: The present invention provides substituted tetrahydrocarbazole and cyclopentanoindole derivatives as antagonists of DP receptor, and as such are useful for the treatment of prostaglandin D2 mediated diseases such as rhinitis, asthma and nasal congestion.

Abstract: The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and effective amount of a phosphodiesterase-4 inhibitor.

Abstract: The present invention provides substituted tetrahydrocarbazole and cyclopentanoindole derivatives as antagonists of DP receptor, and as such are useful for the treatment of prostaglandin D2 mediated diseases such as rhinitis, asthma and nasal congestion.

Abstract: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.

Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.

Abstract: Dihydropyrroloindoles and tetrahydropyridoindoles are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.

Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.

Abstract: Disclosed is a method for rapidly carrying out a hydrogenation of a material capable of absorbing hydrogen. It was discovered that when a powder of a material capable of absorbing hydrogen is ground under a hydrogen pressure, not at room temperature but at a higher temperature (about 300° C. in the case of magnesium) and in the presence of a hydrogenation activator such as graphite and optionally a catalyst, it is possible to transform completely the powder of this material into a hydride. Such a transformation is achieved in a period of time less than 1 hour whereas the known methods call for periods of time as much as 10 times longer. This is an unexpected result which gives rise to a considerable reduction in the cost of manufacture of an hydride, particularly MgH2.

Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.